Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/127—Liposomes
  • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
  • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/06—Phosphorus compounds without P—C bonds
  • C07F9/22—Amides of acids of phosphorus
  • C07F9/24—Esteramides
  • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
  • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/28—Phosphorus compounds with one or more P—C bonds
  • C07F9/54—Quaternary phosphonium compounds
  • C07F9/5407—Acyclic saturated phosphonium compounds
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
  • C07F9/576—Six-membered rings
  • C07F9/59—Hydrogenated pyridine rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
  • C07F9/6503—Five-membered rings
  • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
  • C07F9/6539—Five-membered rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/66—Arsenic compounds
  • C07F9/70—Organo-arsenic compounds
  • C07F9/72—Aliphatic compounds

Definitions

• the present invention relates to new lipophilic compounds having an affinity for nucleic acids. These new compounds can be used as non-viral vectors to introduce a nucleic acid of interest into a chosen host cell or into a chosen host organism.
• lipophilic compounds used in the prior art as non-viral vectors mention may be made of the halides of -1, 2-3-dioleyl trimethylammonium deoxyglycerol, commonly known as DOTAP, the -1, 2-3-dioleyl-trimethylammonium, commonly known as DOTMA , dimethylammonium ethyloxycarbonylcholesterol, commonly known as DC-chol.
• DOTAP -1, 2-3-dioleyl trimethylammonium deoxyglycerol
• DOTMA dimethylammonium ethyloxycarbonylcholesterol
• Phosphonolipids have also been described, such as those described by
• non-viral cationic lipophilic vectors have a reduced capacity for transfection of DNA into cells and have cytotoxic properties with respect to these cells.
• Another objective sought is the obtaining of new non-viral vectors having an improved transfection capacity combined with a low cytotoxicity for the cells to be transfected.
• the applicant has now synthesized new cationic lipophilic compounds, of the mono- or bis-phosphoramide type, and containing a cationic part of the “Onium” type, which have a high capacity for transfection of a nucleic acid into cells, greater than that known non-viral vectors, in particular known phosphonolipids.
• the new lipophilic compounds according to the invention have reduced cytotoxicity properties, compared with the non-viral vector compounds described in the state of the art.
• the subject of the invention is therefore new cationic lipophilic compounds, of the mono- or bisphosphoramide type, and containing a cationic part of the “Onium” type, which are described later in the detailed description of the invention.
• the "Onium" part of the compounds cationic lipophiles of the invention can be an ammonium, a phosphonium or an arsonium, or an organic cation, such as the imidazolium, thiazolium or pyridinium cations.
• the present invention also relates to lipid vesicles, unilamellar or multilamellar, comprising, or consisting mainly or almost exclusively of a lipophilic compound according to the invention, preferably in the form of a complex between said lipophilic compound and a nucleic acid of interest.
• the invention also relates to a complex formed between a nucleic acid of interest and a lipophilic compound as defined above.
• nucleic acid of interest into a host cell or a host organism, using a complex formed between said nucleic acid of interest and a lipophilic compound of the invention, where appropriate presented in the form of unilamellar or multilamellar lipophilic vesicles.
• the invention also relates to a pharmaceutical composition containing, as active principle, at least one complex formed between a nucleic acid of interest and a lipophilic compound as defined above, optionally in combination with one or more physiologically compatible excipients.
• FIGURE 1 illustrates the comparative results of in vitro transfection of cells of the K562 cell line with lipophilic compounds of the prior art and lipophilic compounds according to the invention or with a mixture of a lipophilic compound according to the invention with a lipophilic compound of the state of the prior art.
• the transfection was carried out with DNA of interest encoding the marker protein luciferase.
• parentheses are reported the mass ratios between the lipid compound (s) and the DNA.
• the results of transfection efficiency correspond to the luciferase activity found in the different samples of cells transfected in culture, these results being expressed in TRLU units (Total Relative Light Units), as described in the section "Materials and Methods From Example 5.
• FIGURE 2 illustrates the comparative results of in vitro transfection of cells of the Jurkat cell line with lipophilic compounds of the prior art and lipophilic compounds according to the invention or also with a mixture of a lipophilic compound according to the invention with a lipophilic compound of the state of the prior art.
• the transfection was carried out with DNA of interest encoding the marker protein luciferase.
• parentheses are reported the mass ratios between the lipid compound (s) and the DNA.
• DC-CHOL means the commercial product (3 ⁇ - [N- (N ', N'-dimethylaminoethane) carbamoyl] cholesterol.
• the results of transfection efficiency correspond to the luciferase activity found in the different samples of cells transfected in culture, these results being expressed in TRLU units, as described in the section "Materials and Methods" of Example 5 .
• FIGURE 3 illustrates the comparative results of in vitro transfection of cells of the Daudi cell line with lipophilic compounds of the prior art and lipophilic compounds according to the invention or with a mixture of a lipophilic compound according to the invention with a lipophilic compound of the state of the prior art.
• the transfection has was carried out with a DNA of interest encoding the marker protein luciferase.
• DC-CHOL means the commercial product (3 ⁇ - [N- (N ', N'-dimethylaminoethane) carbamoyl] cholesterol.
• FIGURE 4 illustrates the comparative results of in vitro transfection of mouse cardiomyocyte cells in primary culture with lipophilic compounds of the prior art and lipophilic compounds according to the invention or with a mixture of a lipophilic compound according to the invention with a lipophilic compound of the state of the prior art.
• the transfection was carried out with DNA of interest encoding the marker protein luciferase.
• the different compounds or mixtures of compounds used to form complexes with the DNA of interest before transfection of the cells used according to three distinct charge + / charge - ratios.
• the composition tested contains twice as many positive charges (cationic lipophilic compound) as negative charges (provided by the DNA molecules).
• DOPE dioleylphosphatidylethanolamine
• DD DOPE + DOTAP
• FIGURE 5 illustrates comparative cytotoxicity results between different lipophilic compounds of the invention, lipophilic compounds of the prior art and mixtures of lipophilic compounds of the invention with lipophilic compounds of the prior art.
• FIGURE 6 illustrates the comparative results of in vivo transfection efficiency of a DNA coding for luciferase, between different lipophilic compounds of the invention, different lipophilic compounds of the prior art and mixtures between lipophilic compounds of the invention and lipophilic compounds of the prior art.
• the applicant has synthesized new cationic lipophilic compounds, of the mono-phosphoramide or bis-phosphoramide type, and having a cationic part of the “Onium” type, combining a higher capacity for transfection of cells with a nucleic acid of interest and properties of reduced cytotoxicity, compared to previously known non-viral lipophilic vectors.
• the subject of the invention is a cationic lipophilic compound of general formula (I) below:
• R 1 and R ' 1 each represent, independently of one another, an alkyl chain, an alkenyl chain or a polyalkenyl chain of 10 to 24 carbon atoms, with the polyalkenyl chain having from 2 to 4 double bonds;
• R 2 is a hydrogen atom or an alkyl chain having from 1 to 4 carbon atoms;
• R 3 is a group of the following formula (Ma): - (CH2) n- or (llb) following:
• alkyl is meant according to the invention an aliphatic hydrocarbon group, which can be linear or branched.
• the alkyl chain may be substituted, on one or more of the carbon atoms constituting it, by a group chosen from hydroxy, alkoxy and alkylthio groups.
• a carbon atom of the hydrocarbon chain comprises at most a single substituent.
• at most three carbon atoms of the hydrocarbon chain are substituted by at least one of the above groups.
• alkenyl is meant according to the invention an alkyl group containing a carbon-carbon double bond, which can be located at any point of the hydrocarbon chain.
• polyalkenyl is meant according to the invention an alkyl group containing from two to four carbon-carbon double bonds in the hydrocarbon chain, which can be located at any point of the hydrocarbon chain in relative “malonic” positions.
• organic cation is meant according to the invention any organic chemical group contained in a lipophilic compound of the invention and positively charged in solution.
• anion is meant according to the invention any organic or mineral molecule which is negatively charged in solution.
• the applicant believes that the improved properties of the above lipophilic compounds allowing efficient transfection of a nucleic acid of interest, both in vitro and in vivo, are due to the brittleness of the covalent bond between the lipophilic part and the cationic part of these compounds, said bond being cleaved after the passage of the lipophilic compound through the cell membrane, which releases the cationic part which retains the binding properties to the polyanionic nucleic acid d of interest, and which can be transported to the nucleus of cells.
• the free lipophilic part after cleavage, can be degraded under the action of various cellular enzymes, especially various enzymes found in the cytoplasm.
• the applicant has in fact observed, by measuring the 1 H and 31 P NMR spectrum, that the bond between the phosphorus atom (P) and the nitrogen atom (N) of a cationic lipophilic compound of formula (I ) is rapidly hydrolyzed, in the absence of an enzyme, to a pH value of about 4-5, which is the pH found in the endosomes or intracytoploplasmic lysosomes of the cell.
• the PN bond is completely hydrolyzed after an incubation of the compound of formula (I) for 6 hours at a pH of about 4-5, at a temperature of 20 ° C.
• X " is an anion chosen from CF3CO2 " , CF3SO 3 " ,
• the halogen is chosen from
• a lipophilic compound as defined above is characterized in that group A is a five or six-membered heterocyclic aromatic ring comprising a heteroatom consisting of a nitrogen quaternary linked by a covalent bond to the group R 3 .
• the heterocyclic aromatic ring comprises a second heteroatom chosen from S or N.
• the second heteroatom is N, said second heteroatom is substituted by an alkyl chain of 1 to 4 carbon atoms.
• group A is a thiazolium or an imidazolium, with the second nitrogen heteroatom optionally substituted by an alkyl chain of 1 to 4 carbon atoms.
• Preferred compounds belonging to this first embodiment of the invention are the following: - ditetradecyl iodide 2- (1-methyl-1 H-imidazol-3-ium-3-yl) ethylamidophosphate [compound KLN27]; dioleyl iodide 2- (1-methyl-1H-imidazol-3-ium-3-yl) ethylamidophosphate [compound KLN28];
• a lipophilic compound as defined above is characterized in that group A is a six-membered heterocyclic aromatic ring comprising a quaternary nitrogen heteroatom.
• group A is a pyridinium ring.
• the lipophilic compound of the invention is characterized in that group A is represented by the following formula (III):
• R 13 represents an alkyl chain of 1 to 4 carbon atoms.
• a preferred compound belonging to the second embodiment of a lipophilic compound according to the invention is the compound: - ditetradecyl iodide 2- (1-methyl-1 - / - pyridin-1-ium-4-yl) ethylamidophosphate [compound KLN38]
• a lipophilic compound according to the invention is characterized in that group A is a cation of formula (IV) below:
• R 4 and R 5 each represent, independently of one another, an alkyl chain having from 1 to 4 carbon atoms; and h) R 6 represents an alkyl chain having from 1 to 4 carbon atoms.
• the compounds belonging to the third embodiment above and having a high level of capacity to transfect a nucleic acid in a target cell are preferably those for which the groups R 4 , R 5 and R 6 each represents a methyl group.
• the group R 2 represents hydrogen, a methyl group or an ethyl group.
• Z represents P or A s , and very preferably, Z represents As.
• Preferred compounds belonging to the third embodiment of a lipophilic compound according to the invention are chosen from the following compounds: - iodide of 3 - [[bis (tetradecyloxy) phosphoryl] (methyl) amino] -NNN- trimethylpropanaminium [compound KLN5 ]; 3 - [[bis (oleyloxy) phosphoryl] (methyl) amino] -N.N.N-trimethylpropanaminium iodide [compound KLN6];
• the cationic lipophilic compounds belonging to the first, second and third embodiments above are all compounds of the mono-phosphoramide type.
• an active lipophilic compound is obtained by covalently linking two compounds of the mono-phosphoramide type, the two monophosphoramide compounds being linked to each other by an alkyl chain of 1 to 4 atoms of carbon, which replaces the R 6 group of each of the two mono-phosphoramide compounds, resulting in a bis-phosphoramide compound which also forms part of the invention.
• the subject of the invention is also a lipophilic compound of formula (I) as defined above, said compound being characterized in that group A is a cation of formula (IV) below:
• R 7 and R 8 each represent, independently of one another, an alkyl chain of 1 to 4 carbon atoms, and m) R 9 represents a group of formula (VI) below:
• R 10 represents - (CH 2 ) n- where n is an integer equal to 0, 1, 2, 3 or 4; o) R 11 represents H or an alkyl group of 1 to 4 carbon atoms; and p) R 12 and R ′ 12 each represent, independently of one another, an alkyl chain, an alkenyl chain or a polyalkenyl chain of 10 to 24 carbon atoms, with the polyalkenyl chain having from 2 to 4 double connections;
• the groups R 12 and R 12 are identical to the groups R 1 and R 1 , respectively.
• the groups R 3 and R 10 are identical.
• the groups the groups R 4 and R 5 are identical to the groups R 7 and R 8 , respectively.
• a preferred bis-phosphoramide compound belonging to the fourth embodiment above is the following compound: diiodide of N 1 , N 4 -bis (3-
• the groups R 4 , R 5 and R 6 are preferably identical.
• the groups R 4 , R 5 , R 7 and R 8 are preferably identical.
• the groups R 2 and R 11 are identical.
• the lipid groups R 1 and R ' 1 and, for bis-phosphoramide compounds, also the lipid groups R 12 and R' 12 , each represent, independently of one another, an alkyl chain from 10 to 24 carbon atoms, an alkenyl chain of 10 to 24 carbon atoms or a polyalkenyl chain of 10 to 24 carbon atoms and having from 2 to 4 double bonds per chain.
• the groups R 1 and R ′ 1 are identical.
• the R 12 and R '12 are identical.
• the groups R 1 , R ' 1 , R 12 and R' 12 are all identical.
• At least one group among the groups R 1 , R ' 1 , R 12 and R' 12 , represents an alkyl chain of 10 to 24 carbon atoms
• said alkyl chain is preferably chosen from chains of 14 to 20 atoms of carbon.
• a preferred lipophilic group having an alkyl chain of 10 to 24 carbon atoms is the tetradecyl or myristyl group having 14 carbon atoms.
• At least one group among the groups R 1 , R ' 1 , R 12 and R' 12 , represents an alkenyl chain of 10 to 24 carbon atoms, said alkenyl chain is preferably chosen from chains of 14 to 20 atoms of carbon.
• a preferred lipophilic group having an alkenyl chain of 18 carbon atoms and having an olefinic double bond is the oleyl group.
• At least one group among the groups R 1 , R ' 1 , R 12 and R' 12 , represents a polyalkenyl chain
• said polyalkenyl chain is preferably chosen from chains of 14 to 20 carbon atoms.
• the polyalkenyl chain is chosen from the groups Ci8 : 2 and C ⁇ 8: 3, in which the first number represents the number of carbon atoms in the alkenyl chain and the second number represents the number of double bonds in the chain alkenyl.
• the technical problem of the invention can be solved with groups R 1 , R ' 1 , R 12 and R' 12 , each group representing, independently of one another, an alkyl chain of 10 to 24 carbon atoms, an alkenyl chain of 10 to 24 carbon atoms or a polyalkenyl chain of 10 to 24 carbon atoms and having 2 to 4 double bonds per chain, since these different alkyl, alkenyl or polyalkenyl chains are all sufficiently hydrophobic to allow a lipid compound of the invention to come into contact with the cell membrane, then to enter the cell by crossing the lipid bilayer of the cell membrane, then to reach the nucleus by passing through the membrane nuclear.
• the compound of formula (I) is recovered as defined above by quaternizing the amine -N (R 4 R 5 ) of the compound of formula (VIII) above by an appropriate alkyl halide R 6 -X.
• phase transfer agent such as benzyltriethylammonium chloride
• a phosphite compound of formula (VII) as described above is reacted with a diamine of formula (VIII) as described above, under the same conditions, then reacting 2 equivalents of the compound obtained with an equivalent of an appropriate alkyl dihalide X - R 10 - X.
• any other conventional synthesis method can be implemented by a person skilled in the art to prepare a lipophilic monophosphoramide or bisphosphoramide compound according to the invention.
• the cationic part of the lipophilic compound according to the invention carries the binding properties of said compound with the nucleic acid of interest, said nucleic acid being a polyanionic compound.
• the lipid part of the lipophilic compound represented by the groups R 1 and R ' 1 and, for bisphosphoramide compounds, also by the groups R 12 and R' 12 , allows the lipophilic compound of the invention to bind to the cell membrane , to cross the lipid bilayer of the cell membrane then to reach the cytoplasm and / or the nucleus, at the level of which the nucleic acid of interest is transcribed, or even at the level of which the nucleic acid of interest s' hybrid with a target nucleic acid naturally present in the cell, either in the cytoplasm or in the nucleus.
• nucleic acid for the purposes of the present description, the terms “nucleic acid”, polynucleotide ”and“ oligonucleotide ”include DNA, RNA molecules, DNA / RNA hybrid molecules of more than two nucleotides in length, either in the simple form strand or double strand.
• any of the lipophilic compounds of the invention can be used as such, preferably in solution, to be complexed with a nucleic acid of interest, the introduction of which by transfection into a host cell is sought.
• a lipophilic compound according to the invention is used in the form of lipid vesicles, which are then brought into contact with an acid nucleic acid of interest so as to form a complex between said nucleic acid and the lipid vesicles thus prepared.
• the lipid vesicles are prepared using exclusively a lipophilic monophosphoramide or bisphosphoramide compound of the invention.
• the lipid vesicles can be prepared from a mixture of several lipophilic compounds of the invention, preferably at most four, and very preferably two distinct lipophilic compounds according to the invention. Part of the invention thus forms lipid vesicles comprising a lipophilic monophosphoramide or bisphosphoramide compound chosen from the compounds defined above.
• lipid vesicles essentially consisting of one or more lipophilic monophosphoramide or bisphosphoramide compounds as defined above.
• essentially means lipid vesicles comprising at least 90% by weight of one or a plurality of lipophilic compounds of the invention.
• lipid vesicles consisting exclusively of one or more lipophilic monophosphoramide or bisphosphoramide compounds as defined above.
• the lipid vesicles are prepared by using a mixture of at least one lipophilic compound of the invention with at least one lipophilic compound not forming part of the invention, very preferably a lipophilic compound binding to a nucleic acid and usable as a non-viral vector of a nucleic acid of interest.
• a lipophilic non-viral vector compound is for example a lipophilic compound of the state of the art, such as DOPE, DOTAP, DOTMA, or cholesterol.
• Such lipid vesicles comprise at most four, and preferably at most two, distinct lipophilic compounds according to the invention.
• lipid vesicles comprise at most four, and preferably at most two, distinct lipophilic compounds not forming part of the invention.
• the lipid vesicles encompassed by the second preferred aspect of the fifth embodiment above respectively comprise a single lipophilic compound of the invention, in admixture with a single lipophilic compound not forming part of the invention .
• the proportions of the various lipophilic compounds are variable.
• a weight ratio of the compound of the invention is preferred: other lipophilic compound of between 10:: 1 to 1:: 2, preferably between 6:: 1 and 1:: 1, and most preferably between 4:: 1 and 1:: 1.
• lipid vesicles comprising at least one lipophilic monophosphoramide or bisphosphoramide compound of the invention and at least one other lipophilic compound.
• the lipid vesicles are in the form of unilamellar lipid vesicles, specifically small unilamellar vesicles.
• the lipid vesicles are in the form of multilamellar lipid vesicles.
• the lipid vesicles of the invention can be prepared by any technique known to those skilled in the art, for example by prior dissolution of the lipophilic compound (s) in a solvent, such as an aqueous medium, for example pyrogen-free distilled water or a physiologically compatible saline solution, then sonication of the solution thus obtained.
• a solvent such as an aqueous medium, for example pyrogen-free distilled water or a physiologically compatible saline solution
• the lipid vesicles of the invention can be stored for a long time, for example in frozen form in liquid nitrogen.
• an extemporaneous preparation of these vesicles is preferred, at most a few hours, for example at most 4 hours, before they are brought into contact or incubation with a nucleic acid of interest.
• the nucleic acid of interest which must be introduced into a host cell encodes a protein or a peptide.
• the protein can be any protein useful for carrying out a method of gene therapy, preferably somatic gene therapy, and includes, but is not limited to, cytokines, structural proteins, hormones, antigens, immunogens, receptors etc.
• the nucleic acid of interest encodes a sense or antisense polynucleotide which hybridizes with a target nucleic acid encoding a protein whose inhibition of expression in a cell host is sought.
• the nucleic acid of interest consists of a recombinant vector, preferably a recombinant expression vector, into which is inserted the nucleic acid of interest, the coding sequence of which is placed under the control regulatory sequences, in particular promoter or activator sequence (“enhancer”), necessary for the expression of said nucleic acid of interest in the transfected host cell.
• a recombinant vector preferably a recombinant expression vector
• the nucleic acid of interest linear or circular, single-stranded, or double-stranded, is firstly complexed with a lipophilic monosphoramide or bisphosphoramide compound of the invention, before being introduced, under the form of the complex, in the host cell.
• the complexes are preferably formed by incubation of the nucleic acid with the lipid vesicles defined above.
• the complexes can be formed by incubating the nucleic acid of interest with a lipophilic compound of the invention, or a mixture of several lipophilic compounds of the invention, the complexes thus formed being subsequently used for the transfection of host cells.
• lipid vesicles unilamellar or multilamellar, are formed from the nucleic acid / lipophilic compound (s) complexes previously prepared, then the vesicles are used to transfect the host cells.
• the complexes formed between nucleic acid molecules and molecules of lipophilic compounds comprise a weight ratio of nucleic acid / lipophilic compounds of between 0.5 and 100, advantageously between 1 and 10, and preferably between 2 and 5.
• Another subject of the invention is the use of a lipophilic compound or of a lipid vesicle as defined above, for introducing, in vitro or in vivo, a nucleic acid into a host cell or into a host organism.
• the invention also relates to a method for introducing, in vitro or in vivo, a nucleic acid into a host cell or a host organism, characterized in that it comprises the following steps: a) bringing said nucleic acid into contact with a compound lipophilic or with a lipid vesicle as defined above, in order to obtain a complex between said nucleic acid, on the one hand, and said compound or said lipid vesicle, on the other hand; b) incubating the host cell with the complex formed in step a), or administering, preferably by injection, the complex formed in step a) to the host organism.
• said host cell is a non-human mammalian cell or a human cell
• the host organism is a man or a non-human mammal, although the application of the above method cannot be excluded in other higher organisms such as plants.
• the invention also relates to a complex formed between a nucleic acid and a lipophilic phosphoramide or bisphosphoramide compound or a lipid vesicle as defined above.
• the invention also relates to a composition
• a composition comprising a complex formed between a nucleic acid and a lipophilic phosphoramide or bisphosphoramide compound or a lipid vesicle as defined above.
• the complexes formed between a nucleic acid of interest and a lipophilic compound or a lipid vesicle of the invention can be administered by any suitable method allowing their introduction into the cells of a man or of an animal, such as by injection into interstitial tissue species (heart, muscle, skin, lung, liver, intestines, etc.).
• the complexes are presented in the form of a composition also containing a physiologically compatible vehicle.
• the composition containing these complexes is in a form suitable for administration by aerosol, for example for inhalation.
• the quantity of DNA, RNA or DNA / RNA of interest for a dose injectable is advantageously between 0.005 mg / kg and 50 mg / kg of the weight of the man or animal to be treated.
• the amount of nucleic acid ranges from 0.005 mg / kg to 20 mg / kg, and most preferably from 0.05 mg / kg to 5 mg / kg.
• nucleic acid in a dose for injection, depending in particular on the pathology to be treated and the injection site.
• the quantity of nucleic acid for an injectable dose is determined by a person skilled in the art.
• the invention also relates to a method for introducing in vivo a nucleic acid of interest into the cells of a host organism, said method comprising the following steps: a) a) bringing said nucleic acid into contact with a lipophilic compound or with a lipid vesicle as defined above in order to obtain a complex between said nucleic acid, on the one hand, and said compound or said lipid vesicle, on the other hand; b) administering the complexes formed in step a) to said host organism.
• the host organism is preferably a human or a non-human mammal, although it can also be a plant.
• the complexes formed between a nucleic acid of interest and a lipophilic compound or a lipid vesicle of the invention are present in a suitable liquid solution, such as sterile and pyrogen-free distilled water, in amounts of suitable complexes. .
• a suitable liquid solution such as sterile and pyrogen-free distilled water
• the solution can be used as it is, or also contain one or more stabilizing agents, such as Tween® (20, 40, 60 or 80), NaCl, or even DMPE-PEG 5000.
• the present invention also relates to a pharmaceutical composition
• a pharmaceutical composition comprising a complex formed between a nucleic acid of interest and a lipophilic compound or a lipid vesicle of the invention, where appropriate in combination with one or more physiologically compatible vehicles or excipients.
• the organic layer was washed twice with 5 ml of water and then dried over magnesium sulfate.
• the solvents were removed in vacuo.
• the crude dioleylbromopropylphosphoramide was obtained in the form of an oil.
• the final reaction yield was 80%.
• EXAMPLE 5 Transfection in vitro of a nucleic acid of interest complexed with a lipophilic compound according to the invention.
• the cell lines K562, Jurkat, Daudi and HeLa were used.
• the cells were cultured in RPMI-1640 medium or in MEM culture medium supplemented with 10% fetal calf serum (SVF), 0.2 mM glutamine, 100 U / L of penicillin, 100 U / ml of streptomycin and 1% fungizone. All the cells were maintained in an atmosphere at 5% CO 2 at the temperature of 37 ° C.
• the plasmid used is the plasmid pTG11033 encoding the luciferase protein under the control of the cytomegalovirus promoter (pCMV), developed by the company TRANSGENE (Strasbourg, France).
• Each of the cationic phosphonolipids was prepared individually or in combination with the neutral lipid DOPE (sold by the company SIGMA CHEMICALS, Saint-Quentin Fallavier, France).
• the phosphonolipids were formulated by mixing solutions of the different lipids in chloroform in glass tubes, then removing the chloroform by evaporation on a rotary evaporator, in order to obtain dry films of lipids.
• Small unilamellar vesicles were prepared by sonicating the compounds for ten minutes in a sonicator device (sold by the company PROLABO, Paris, France).
• a sonicator device sold by the company PROLABO, Paris, France.
• the plasmid pTG11033 was first diluted in sterile, pyrogen-free distilled water, then added to the lipid solution.
• the cationic phosphonolipid / DNA complexes were stored for 30 minutes at room temperature before being administered to animals, or used for in vitro transfections.
• the first type of preparation 12.5 ⁇ g of cationic lipid compound was mixed with 4 ⁇ g of DNA (the plasmid pTG 11033).
• the second type of preparation 25 ⁇ g of cationic lipid compound are mixed with 8 ⁇ g of DNA (the plasmid pTG 11033).
• the complexes were formulated either (i) with a cationic lipid compound of the invention used alone or (ii) with a mixture of a lipid compound of the invention and DOPE (dioleylphosphatidyl ethanolamine).
• Non-adherent cells (cell lines K562, Jurkat and Daudi) were cultured in 75 cm 2 culture plates. For the transfection tests, the cells were seeded in 24-well tissue culture plates, at a rate of 500,000 cells per well. For the adherent cell line (HeLa), the cells were seeded in 24-well tissue culture plates at the rate of 150,000 cells per well.
• the cells were incubated in the tissue culture plates for 24 hours before the transfection step, then incubated overnight in a culture incubator in a humid atmosphere at 5% CO 2 , at a temperature of 37 ° C. .
• the transfection of the cells was carried out according to the technique described by FELGNER et al. (Proc. Natl. Acad. Sci. USA, 1987, vol. 84: 7413), with the following modifications:
• the appropriate amounts of cationic lipids and of the plasmid vector PTG11033 were complexed in 100 ⁇ l of an OptiMEM solution (Ref. 31985-047, Gibco BRL / Life Technologies / Cergy- Pontoise, France) supplemented with L-glutamine, Sodium bicarbonate (2.4 g / l), HEPES buffer, sodium pyruvate, hypoxanthine, thymidine, growth factor and red phenol (1.1 mg / l).
• the preparation is identical to that described in Section A.2 above.
• 100 ⁇ l of the cationic phospholipid / DNA complex solution was added to each culture well.
• the cells were added with 2 ml of the appropriate culture medium. After an additional 48 hour incubation at 37 ° C., the cells were tested for the expression of the gene coding for luciferase, using a chemiluminescent kit (sold by the company PROMEGA, Charbonippos, France). The tests were carried out according to the manufacturer's recommendations. The results are expressed in TRLU units (for “Total Relative
• the relative cytotoxicity of the different cationic phosphonolipid / DNA complexes was determined as a representation of the number of living cells after the transfection experiment, measured using a chemiluminescent test, the CYTOLITE® test (marketed by the company PACKARD, France), according to the manufacturer's recommendations.
• the cells were transfected as described in Section A.3 above.
• the cells were seeded in the wells of a 24-well plate, at a rate of: - 500,000 cells per well for the non-adherent cell lines (K 562, Jurkat, Daudi); and
• the cells were treated for transfection as described above and incubated for an additional 48 hours. After incubation, the cytotoxicity test was carried out according to the manufacturer's recommendations.
• RLU Relative Light Units
• the toxicity index represents the ratio between the number of living cells in the control cultures (without cationic lipid / DNA complex) and the number of living cells in the culture wells containing the transfected cells.
• each preparation of lipid vector / DNA complexes described in section A.2. of the “Materials and methods” section above was used on each of the cell lines described in section A.1 of the “Materials and Methods” section above, at the same time, and under conditions identical to those described in section A.3 of the “Materials and Methods” section above.
• FIGS. 1, 2, 3 and 4 show that the cationic lipid compounds of the invention, which contain a phosphoramide bond are more effective and less cytotoxic than the compounds of the prior art such as the compound EG 308 , and that commonly marketed transfection agents, such as DOTAP and PEI.
• Cationic lipid / DNA complexes are produced at a charge ratio (+/-) of 4 and are administered to mice of the Swiss line six weeks old, by a single injection into the tail vein. Each animal received a volume of 200 ⁇ l of a solution of the lipid / DNA complex tested, corresponding to 50 ⁇ g of plasmid DNA coding for the luciferase protein. The animals were killed 24 hours after the injection and each organ of interest was frozen in liquid nitrogen, then stored at the temperature of -70 ° C.
• the frozen tissues were ground with steel balls in a 2 ml Epperdorf type tube with a round bottom using a device of the Mill MM300 mixer type (sold by the company QIAGEN; reference: 0030120-094).
• Protein extraction from each tissue was carried out by incubating the ground tissue in a PLB lysis buffer (Promega) then centrifugation at 10,000 g, 10 min at 4 ° C.
• the luciferase activity was tested on the lysis supernatants using the chemiluminescence test "Luciferase Assay System” sold by the company PROMEGA.
• the cationic lipid / plasmid DNA complexes were prepared as described in Example 5, with charge ratios (+/-) varying from 0 to 6.
• the lipid / DNA complexes were administered to mice of the Swiss line. six weeks of age, by inhalation of 150 ⁇ l of the complex solution, using an aerosol device. The inhalation was carried out using the “Microsprayer” aerosol device (sold by the company PENN-CENTURY, Inc.), which allows atomization to be carried out directly in the trachea.
• Each animal received a dose of 50 ⁇ g of plasmid DNA coding for the luciferase protein, in the form of the lipid / DNA complex.
• the animals were sacrificed 72 hours after the injection.
• the lungs were collected, then frozen in liquid nitrogen and stored at -70 ° C. Protein extraction from frozen lungs and measurement of RLU units per mg protein were performed as described in section A.1 above.
• the results are shown in FIG. 6.
• the results of FIG. 6 show the advantage of the lipophilic transfection compounds according to the invention, compared with the lipophilic compounds of the state of the art or even with DNA alone.
• Compounds with a C18: 1 hydrophobic chain are particularly effective at transfecting the lungs of mice, whether used alone or in combination with cholesterol.
• the KLN20 compound is the most effective.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Genetics & Genomics (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Engineering & Computer Science (AREA)
• Biotechnology (AREA)
• Biomedical Technology (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)
• Biophysics (AREA)
• Pharmacology & Pharmacy (AREA)
• Microbiology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Plant Pathology (AREA)
• Epidemiology (AREA)
• Physics & Mathematics (AREA)
• Medicinal Chemistry (AREA)
• Dispersion Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicinal Preparation (AREA)
• Saccharide Compounds (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=32116497

Family Applications (1)

Country Status (6)

Families Citing this family (4)

Family Cites Families (1)

• 2002
  • 2002-11-08 FR FR0214044A patent/FR2846967B1/fr not_active Expired - Fee Related
• 2003
  • 2003-11-07 CA CA2505414A patent/CA2505414C/en not_active Expired - Fee Related
  • 2003-11-07 EP EP03786052A patent/EP1562963A1/de not_active Ceased
  • 2003-11-07 US US10/534,236 patent/US7667070B2/en not_active Expired - Fee Related
  • 2003-11-07 WO PCT/FR2003/050116 patent/WO2004043970A1/fr not_active Application Discontinuation
  • 2003-11-07 AU AU2003295057A patent/AU2003295057A1/en not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events